Modulight

1,03

EUR

−1,9 %

Företagskund

MODU

First North Finland

Medicinsk Utrustning & Service

Hälsovård

2 687 följer bolaget

Jämför

−1,9%

+7,29%

+11,35%

−3,74%

−8,04%

−7,21%

−90,42%

−90,59%

Modulight är verksamt inom teknikbranschen. Bolaget designar, marknadsför och producerar biomedicinska laserprodukter som används inom onkologi, genetik och oftalmologi. Kunderna består primärt av sjukhus och företagskunder verksamma inom medicinteknik. Utöver huvudverksamheten erbjuds även diverse mervärdestjänster. Störst verksamhet återfinns inom US.

Läs mera

Börsvärde

43,9 mn EUR

Omsatt (värde)

10,06 tn EUR

P/E (just.) (24e)

−5,7

EV/EBIT (adj.) (24e)

−4,05

EV/S (24e)

8,53

Direktavkastnings- % (24e)

Coverage

Rekommendation

Minska

Riktkurs

0.90 EUR

Uppdaterad

2024-10-22

Disclaimer

Antti Siltanen

Analytiker

Latest research

Latest analysis report

Released: 2024-10-22

Latest extensive report

Released: 2023-03-21

Finansiell kalender

21/2

2025

Bokslutskommuniké '24

25/4

2025

Delårsrapport Q1'25

2/5

2025

Bolagsstämma '25

Risk

Business risk

Valuation risk

Låg

Hög

VisarAlla typer av innehåll

Regulatoriskt pressmeddelande2024-12-31 09:15

Modulight’s financial reporting and Annual General Meeting in 2025

Modulight

Regulatoriskt pressmeddelande2024-12-30 14:00

Change in Modulight Corporation’s holding of treasury shares and annulment of option rights

Modulight

Analytikerkommentar2024-12-20 06:24 av

Antti Siltanen

Modulight receives order worth 0.5 MEUR

Delivery of the order is scheduled for the second half of 2025 and the first half of 2026.

Modulight

Välkommen med i Inderes community!

Skapa ett gratis användarkonto och försäkra dig om att inte missa några börsnyheter av intresse för precis dig!

Inderes användarkonto

Ger dig möjlighet att följa bolag och beställa notifikationer

Tillgång till analytikerkommentarer och rekommendationer

Tillgång till vårt aktiescreeningsverktyg och andra populära verktyg

Skapa användarkonto

Drug development investment: Value creation through M&As and licensing agreements

Artikel2024-12-19 11:07 av

Antti Siltanen

Drug development investment: Value creation through M&As and licensing agreements

The fourth part of our series of articles focusing on investing in Life Science companies deals with value creation in drug development companies through M&As and licensing agreements.

Faron Pharmaceuticals Herantis Pharma Orion Modulight

Regulatoriskt pressmeddelande2024-12-19 09:47

Inside Information: Modulight Has Received an Order Worth EUR 0.5 Million

Modulight

Regulatoriskt pressmeddelande2024-12-19 08:02

Modulight Corporation's Shareholders’ Nomination Committee Composition

Modulight

Analytikerkommentar2024-12-03 10:21 av

Antti Siltanen

Regulation of drug development

The third part in our series of articles on investing in Life Science companies deals with regulatory issues. Regulatory processes are demanding and time-consuming, and failure to comply can be disastrous for a drug development company.

Faron Pharmaceuticals Herantis Pharma Orion Mendus Modulight

Video2024-12-02 14:00

Life Science Companies as Investments | Life Science Night Dec. 2, 2024

Antti Siltanen, Life Science Analyst, PhD, talks about life science companies as investments.

Aiforia Technologies BBS-Bioactive Bone Substitutes Bioretec Biohit Faron Pharmaceuticals Modulight Nexstim Orion Bittium Detection Technology Optomed Revenio Group Nightingale Health Herantis Pharma Nanoform Finland

Analytikerkommentar2024-11-08 11:52 av

Antti Siltanen

Pay-Per-Treatment model brings Modulight order intake

Modulight announced on Friday that it has secured contracts with a minimum cumulative value of EUR 1.5 MEUR over the next two years. The news adds further visibility to the progress of the revenue and PPT model in the coming years

Modulight

Regulatoriskt pressmeddelande2024-11-08 08:25

Inside Information: Modulight has received PPT purchase orders worth of 1.5 million dollars

Modulight

Aktieanalys2024-10-22 06:51 av

Antti Siltanen

Modulight Q3'24: No clear signs of growth yet

Modulight's Q3 report showed no clear signs of a return to growth and revenue landed below expectations. Earnings and cash flow were roughly in line with our forecasts due to lower-than-expected costs.

Modulight

Analytikerkommentar2024-10-18 12:41 av

Antti Siltanen

Modulight Q3'24 flash comment: Revenue missed expectations - profit and cash flow close to forecasts

Modulight's revenue was well below our expectations, but profit and cash flow were close to our forecasts. Revenue was negatively impacted by the transition to the PPT (pay-per-treatment) model and delays in prototype deliveries.

Modulight

Regulatoriskt pressmeddelande2024-10-18 10:00

Modulight: Cash flow development continued positive, progress with new business models

Modulight

Analytikerkommentar2024-10-16 06:22 av

Antti Siltanen

Modulight Q3'24 preview: Eye laser and clinical studies as revenue drivers

Modulight will publish its Q3 results on Friday, October 18 at 1:00 pm EEST. We expect moderately growing revenue from Phase III clinical projects and ophthalmic lasers.

Modulight

Pressmeddelande2024-10-14 10:00